Trial purpose
Cancer treatment
Tumor type
Haematological
Age
18+
Clinical summary
Summary
Eligible participants will receive the study drug (called DZD8586). Treatment will start from 50mg once daily. If this is tolerated, subsequent cohorts will test increasing doses.
Conditions
This trial is treating people with relapsed or refractory B-cell Non-Hodgkin Lymphoma
Eligibility
Inclusion
- Male or female participants who have provided ICF with age ≥ 18 yrs
- ECOG performance 0-2, no deterioration in the past 2 weeks
- Participants with relapsed or refractory B-NHL must have cytologically or histologically confirmed B-cell lymphoma
- Adequate bone marrow reserve and organ system functions
- Participants willing to comply with contraceptive restrictions
Exclusion
- Any unresolved > Grade 1 adverse event at the time of starting study treatment with the exception of alopecia.
- Prior history of allogeneic hematopoietic stem cell transplantation
- Stem cell transplantation, cell therapy, or gene therapy within 90 days. Approved small molecule therapy within 5 half-lives, investigational small molecule therapy within 14 days. Monoclonal antibodies and antibody-drug conjugates within 28 days Radiation therapy within 1 weeks
- Live attenuated vaccines or viral vector vaccines within 4 weeks. Major surgery or significant traumatic injury within 4 weeks. History of stroke or intracranial hemorrhage within 6 months
- Participants with non-CNSL presence of CNS or intraocular lymphoma lesions.
- CNSL participants with systemic presence of lymphoma, unable to complete lumbar puncture, under systemic corticosteroids at a dose > 8 mg/day (dexamethasone equivalent dose) within 14 days or requiring immunosuppressive or biologic therapy."
- Participants with infectious disease:
- Clinically significant cardiac disorders or abnormalities
- Another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer.
- Refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption
- Women who are breast feeding
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Dizal Pharmaceuticals
Scientific Title
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information